Security record · archived quarter
RLMD
Relmada Therapeutics, Inc. · Healthcare · Biotechnology
6Tracked holders
—Δ holders
857.82KShares held
$2.57MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 52 | +17 | 37.42M | $258.91M | +22 | −5 |
| Q1 2026 | 36 | +1 | 37.39M | $260.09M | +3 | −2 |
| Q4 2025 | 35 | +5 | 26.87M | $129.62M | +5 | — |
| Q3 2025 | 8 | 0 | 1.94M | $3.90M | — | — |
| Q2 2025 | 7 | +1 | 1.68M | $1.01M | +1 | — |
| Q1 2025 | 4 | 0 | 703.26K | $189,901 | — | — |
| Q4 2024 | 4 | -3 | 701.66K | $364,906 | — | −3 |
| Q3 2024 | 6 | 0 | 1.19M | $3.85M | — | — |
| Q2 2024 | 6 | — | 857.82K | $2.57M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 260.50K | — | $781,692 | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 260.50K | — | $781,692 | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 203.26K | — | $609,783 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 156.62K | — | $469,857 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 88.78K | — | $266,325 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 84.31K | — | $252,939 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 64.36K | — | $193,071 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 103 holders, 83.66M shares, $576.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API